Trial Profile
A Phase 2 Trial of Oxaliplatin and Sorafenib Combination in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Relapsed After a Cisplatin Based Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2015
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Sorafenib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 19 Dec 2012 Status changed from recruiting to completed.
- 19 Dec 2012 Additional information source identified and integrated ClinicalTrials.gov NCT01262482.
- 01 Dec 2011 According to ClinicalTrials.gov this study has been completed.